Lei Xu
Associate Prof., Radiation Oncology
Lei Xu
See the Xu Lab PagePublications
HideLeveraging insights from cancer to improve tuberculosis therapy.
Trends Mol Med. 2024;:ePub - PMID: 39142973 - DOI: 10.1016/j.molmed.2024.07.011
Integrating Ataxia Evaluation into Tumor-Induced Hearing Loss Model to Comprehensively Study NF2-Related Schwannomatosis.
Cancers (Basel). 2024;16(11):ePub - PMID: 38893082 - PMCID: PMC11171041 - DOI: 10.3390/cancers16111961
Normalizing granuloma vasculature and matrix improves drug delivery and reduces bacterial burden in tuberculosis-infected rabbits.
Proc Natl Acad Sci U S A. 2024;121(14):e2321336121 - PMID: 38530888 - PMCID: PMC10998582 - DOI: 10.1073/pnas.2321336121
Mathematical model of oxygen, nutrient, and drug transport in Tuberculosis Granulomas.
PLoS Comput Biol. 2024;20(2):e1011847 - PMID: 38335224 - PMCID: PMC10883541 - DOI: 10.1371/journal.pcbi.1011847
Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models.
Proc Natl Acad Sci U S A. 2023;120(6):e2219199120 - PMID: 36724255 - PMCID: PMC9963691 - DOI: 10.1073/pnas.2219199120
Novel patient-derived xenograft and cell line models for therapeutic screening in NF2-associated schwannoma.
J Pathol. 2022;257(5):620-634 - PMID: 35394061 - DOI: 10.1002/path.5908
Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy.
Proc Natl Acad Sci U S A. 2021;118(45):ePub - PMID: 34725151 - PMCID: PMC8609309 - DOI: 10.1073/pnas.2105323118
Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models.
Sci Transl Med. 2021;13(602):ePub - PMID: 34261799 - PMCID: PMC8409338 - DOI: 10.1126/scitranslmed.abd4816
Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas
Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma.
Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma.
Proc Natl Acad Sci U S A. 2019;116(6):2210-2219 - PMID: 30659155 - PMCID: PMC6369817 - DOI: 10.1073/pnas.1818357116
A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.
Nat Protoc. 2019;14(2):541-555 - PMID: 30617350 - PMCID: PMC6571021 - DOI: 10.1038/s41596-018-0105-7
Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models.
Proc Natl Acad Sci U S A. 2018;115(9):E2077-E2084 - PMID: 29440379 - PMCID: PMC5834719 - DOI: 10.1073/pnas.1719966115
A cerebellar window for intravital imaging of normal and disease states in mice.
Nat Protoc. 2017;12(11):2251-2262 - PMID: 28981123 - PMCID: PMC5918134 - DOI: 10.1038/nprot.2017.101
Rationally combining anti-VEGF therapy with radiation in NF2 schwannoma.
J Rare Dis Res Treat. 2017;1(2):51-55 - PMID: 28191549 - PMCID: PMC5300073
Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.
Proc Natl Acad Sci U S A. 2016;113(16):4470-5 - PMID: 27044097 - PMCID: PMC4843449 - DOI: 10.1073/pnas.1525349113
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.
Proc Natl Acad Sci U S A. 2016;113(16):4476-81 - PMID: 27044098 - PMCID: PMC4843473 - DOI: 10.1073/pnas.1525360113
Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model.
Proc Natl Acad Sci U S A. 2015;112(47):14676-81 - PMID: 26554010 - PMCID: PMC4664377 - DOI: 10.1073/pnas.1512570112
Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery.
Proc Natl Acad Sci U S A. 2015;112(6):1827-32 - PMID: 25624495 - PMCID: PMC4330784 - DOI: 10.1073/pnas.1424563112
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma.
TGF-? blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma.
Proc Natl Acad Sci U S A. 2012;109(41):16618-23 - PMID: 22996328 - PMCID: PMC3478596 - DOI: 10.1073/pnas.1117610109
Normalization of the vasculature for treatment of cancer and other diseases.
Physiol Rev. 2011;91(3):1071-121 - PMID: 21742796 - PMCID: PMC3258432 - DOI: 10.1152/physrev.00038.2010
PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer.
Clin Cancer Res. 2011;17(11):3638-48 - PMID: 21459800 - PMCID: PMC3107920 - DOI: 10.1158/1078-0432.CCR-10-2456
CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?
Clin Cancer Res. 2011;17(8):2074-80 - PMID: 21349998 - PMCID: PMC3079023 - DOI: 10.1158/1078-0432.CCR-10-2636
TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models.
Clin Cancer Res. 2011;17(6):1415-24 - PMID: 21278244 - PMCID: PMC3060297 - DOI: 10.1158/1078-0432.CCR-10-2429
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
J Neurooncol. 2011;103(2):325-32 - PMID: 20821342 - PMCID: PMC4090923 - DOI: 10.1007/s11060-010-0390-7
Epigenetic markers in rectal cancer.
Clin Cancer Res. 2010;16(10):2699-701 - PMID: 20460492 - DOI: 10.1158/1078-0432.CCR-10-0559
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.
Cancer Res. 2009;69(20):7905-10 - PMID: 19826039 - PMCID: PMC2859041 - DOI: 10.1158/0008-5472.CAN-09-2099
Correlation of blood and physiologic markers with effect of bevacizumab (BV) with chemoradiation therapy in rectal cancer (RC).
J Clin Oncol. 2008;26(15_suppl):4096 - PMID: 27949464
Perivascular nitric oxide gradients normalize tumor vasculature.
Nat Med. 2008;14(3):255-7 - PMID: 18278052 - DOI: 10.1038/nm1730
alphaPlGF: a new kid on the antiangiogenesis block.
Cell. 2007;131(3):443-5 - PMID: 17981110 - DOI: 10.1016/j.cell.2007.10.023
Down-regulation of placenta growth factor by promoter hypermethylation in human lung and colon carcinoma.
Mol Cancer Res. 2007;5(9):873-80 - PMID: 17704140 - DOI: 10.1158/1541-7786.MCR-06-0141
Do the dietary supplements epigallocatechin gallate or vitamin e cause a radiomodifying response on tumors in vivo? A pilot study with murine breast carcinoma.
J Soc Integr Oncol. 2007;5(1):11-7 - PMID: 17309809 - DOI: 10.2310/7200.2006.033
Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis.
Cancer Res. 2006;66(7):3360-4 - PMID: 16585153 - DOI: 10.1158/0008-5472.CAN-05-2655
Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models.
Cancer Res. 2006;66(8):3971-7 - PMID: 16618713 - DOI: 10.1158/0008-5472.CAN-04-3085
Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model.
Cancer Res. 2005;65(13):5711-9 - PMID: 15994946 - DOI: 10.1158/0008-5472.CAN-04-4313
NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels.
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.
Cancer Cell. 2004;6(6):553-63 - PMID: 15607960 - DOI: 10.1016/j.ccr.2004.10.011
The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis.
Nature. 2004;428(6980):328-32 - PMID: 15029197 - DOI: 10.1038/nature02329
Hypoxia-induced activation of p38 mitogen-activated protein kinase and phosphatidylinositol 3'-kinase signaling pathways contributes to expression of interleukin 8 in human ovarian carcinoma cells.
Clin Cancer Res. 2004;10(2):701-7 - PMID: 14760093 - DOI: 10.1158/1078-0432.ccr-0953-03
Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis.
Circ Res. 2003;93(9):e88-97 - PMID: 14525808 - PMCID: PMC2755542 - DOI: 10.1161/01.RES.0000099243.20096.FA
Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts.
Clin Cancer Res. 2003;9(11):4221-6 - PMID: 14519649
Specific Keynote: Molecular determinants of angiogenesis in ovarian cancer
Gynecologic Oncology. 2003;88:S290S36
Specific keynote: molecular determinants of angiogenesis in ovarian cancer.
Gynecol Oncol. 2003;88(1 Pt 2):S29-36; discussion S37-42 - PMID: 12586082 - DOI: 10.1006/gyno.2002.6680
Tumour biology: herceptin acts as an anti-angiogenic cocktail.
Nature. 2002;416(6878):279-80 - PMID: 11907566 - DOI: 10.1038/416279b
Expression of metastasis-related genes in human epithelial ovarian tumors.
Int J Oncol. 2002;20(1):5-13 - PMID: 11743636
Pancreas microenvironment promotes VEGF expression and tumor growth: novel window models for pancreatic tumor angiogenesis and microcirculation.
Lab Invest. 2001;81(10):1439-51 - PMID: 11598156 - DOI: 10.1038/labinvest.3780357
Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo.
Cancer Res. 2001;61(16):6020-4 - PMID: 11507045
In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy.
Nat Med. 2001;7(7):864-8 - PMID: 11433354 - DOI: 10.1038/89997
Interleukin 8: an autocrine growth factor for human ovarian cancer.
Oncol Res. 2000;12(2):97-106 - PMID: 11132928 - DOI: 10.3727/096504001108747567
Acidic pH-induced elevation in interleukin 8 expression by human ovarian carcinoma cells.
Cancer Res. 2000;60(16):4610-6 - PMID: 10969814
Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
Int J Oncol. 2000;16(3):445-54 - PMID: 10675474 - DOI: 10.3892/ijo.16.3.445
Interferon-mediated antiangiogenic therapy
Journal of National Cancer Institute. 2000;1092:4-12
Critical determinants of neoplastic angiogenesis
The Cancer Journal. 2000;6 Suppl 3:S225-36 - PMID: 10874492
Hypoxia-induced elevation in interleukin-8 expression by human ovarian carcinoma cells.
Cancer Res. 1999;59(22):5822-9 - PMID: 10582705
Therapy of human ovarian cancer by transfection with the murine interferon beta gene: role of macrophage-inducible nitric oxide synthase.
Hum Gene Ther. 1998;9(18):2699-708 - PMID: 9874268 - DOI: 10.1089/hum.1998.9.18-2699
Suppression of tumorigenicity and metastasis of human renal carcinoma cells by infection with retroviral vectors harboring the murine inducible nitric oxide synthase gene.
Hum Gene Ther. 1998;9(6):845-54 - PMID: 9581907 - DOI: 10.1089/hum.1998.9.6-845
Abrogation of tumorigenicity and metastasis of murine and human tumor cells by transfection with the murine IFN-beta gene: possible role of nitric oxide.
Clin Cancer Res. 1997;3(12 Pt 1):2283-94 - PMID: 9815626
Nitric oxide-mediated apoptosis of K-1735 melanoma cells is associated with downregulation of Bcl-2.
Oncogene. 1997;15(7):771-9 - PMID: 9266963 - DOI: 10.1038/sj.onc.1201239
Use of retroviral vectors encoding murine inducible nitric oxide synthase gene to suppress tumorigenicity and cancer metastasis of murine melanoma.
Cancer Biother Radiopharm. 1997;12(3):167-75 - PMID: 10851463 - DOI: 10.1089/cbr.1997.12.167